Skip to content

Study · Randomized controlled trial · 2012

4 results

Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis.

Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics27 Mar 2012Cited by 56 (Europe PMC)

PMID22459918 (opens in a new tab)DOI10.1016/j.ijgo.2012.01.009 (opens in a new tab)PepBankPUB-22459918
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, dienogest was non-inferior to leuprolide for response at all predefined pain-relief thresholds.

    In plain wordsIn women with endometriosis, dienogest was non-inferior to leuprolide at all predefined pain-relief thresholds.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPain relief responder thresholds
    Study

    n: not reported in source

    Comparator
    Dienogest
    Analysis
    Secondary
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Dienogest was non-inferior to LA for treatment response using all predefined thresholds of pain relief and provided equivalent improvements in B&B symptoms and signs.
    1 context sentence
    Summary · context
    A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, c…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, leuprolide and dienogest provided equivalent improvements in Biberoglu and Behrman symptoms and signs.

    In plain wordsIn women with endometriosis, leuprolide and dienogest improved symptom and sign scores equally.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedBiberoglu and Behrman symptoms and signs
    Study

    n: not reported in source

    Comparator
    Dienogest
    Analysis
    Secondary
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Dienogest was non-inferior to LA for treatment response using all predefined thresholds of pain relief and provided equivalent improvements in B&B symptoms and signs.
    1 context sentence
    Summary · context
    A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, c…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, specific quality-of-life measures improved more with dienogest than leuprolide.

    In plain wordsIn women with endometriosis, specific quality-of-life measures improved more with dienogest than leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseSpecific quality-of-life measures
    Study

    n: not reported in source

    Comparator
    Dienogest
    Analysis
    Secondary
    Outcome group
    Quality of life · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with LA, DNG was associated with pronounced improvements in specific quality-of-life measures.
    1 context sentence
    Summary · context
    A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, c…
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, estrogen levels decreased during leuprolide treatment.

    In plain wordsIn women with endometriosis, estrogen levels decreased during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseEstrogen levels
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No clinically relevant changes in laboratory parameters were observed during DNG treatment, whereas estrogen levels decreased in the LA group.
    1 context sentence
    Summary · context
    A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, c…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.